Literature DB >> 8890201

Antibacterial activity of antileukoprotease.

P S Hiemstra1, R J Maassen, J Stolk, R Heinzel-Wieland, G J Steffens, J H Dijkman.   

Abstract

Antileukoprotease (ALP), or secretory leukocyte proteinase inhibitor, is an endogenous inhibitor of serine proteinases that is present in various external secretions. ALP, one of the major inhibitors of serine proteinases present in the human lung, is a potent reversible inhibitor of elastase and, to a lesser extent, of cathepsin G. In equine neutrophils, an antimicrobial polypeptide that has some of the characteristics of ALP has been identified (M. A. Couto, S. S. L. Harwig, J. S. Cullor, J. P. Hughes, and R. I. Lehrer, Infect. Immun. 60:5042-5047, 1992). This report, together with the cationic nature of ALP, led us to investigate the antimicrobial activity of ALP. ALP was shown to display marked in vitro antibacterial activity against Escherichia coli and Staphylococcus aureus. On a molar basis, the activity of ALP was lower than that of two other cationic antimicrobial polypeptides, lysozyme and defensin. ALP comprises two homologous domains: its proteinase-inhibitory activities are known to be located in the second COOH-terminal domain, and the function of its first NH2-terminal domain is largely unknown. Incubation of intact ALP or its isolated first domain with E. coli or S. aureus resulted in killing of these bacteria, whereas its second domain displayed very little antibacterial activity. Together these data suggest a putative antimicrobial role for the first domain of ALP and indicate that its antimicrobial activity may equip ALP to contribute to host defense against infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890201      PMCID: PMC174407          DOI: 10.1128/iai.64.11.4520-4524.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Antimicrobial polypeptides of human neutrophils.

Authors:  R I Lehrer; T Ganz
Journal:  Blood       Date:  1990-12-01       Impact factor: 22.113

2.  Location of the protease-inhibitory region of secretory leukocyte protease inhibitor.

Authors:  S P Eisenberg; K K Hale; P Heimdal; R C Thompson
Journal:  J Biol Chem       Date:  1990-05-15       Impact factor: 5.157

3.  Quantity of anti-leucoprotease relative to alpha 1-proteinase inhibitor in peripheral airspaces of the human lung.

Authors:  J A Kramps; C Franken; J H Dijkman
Journal:  Clin Sci (Lond)       Date:  1988-10       Impact factor: 6.124

4.  Secretory leukocyte protease inhibitor binding to mRNA and DNA as a possible cause of toxicity to Escherichia coli.

Authors:  K W Miller; R J Evans; S P Eisenberg; R C Thompson
Journal:  J Bacteriol       Date:  1989-04       Impact factor: 3.490

5.  Elafin: an elastase-specific inhibitor of human skin. Purification, characterization, and complete amino acid sequence.

Authors:  O Wiedow; J M Schröder; H Gregory; J A Young; E Christophers
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

6.  Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry.

Authors:  R I Lehrer; A Barton; T Ganz
Journal:  J Immunol Methods       Date:  1988-04-06       Impact factor: 2.303

7.  The location of inhibitory specificities in human mucus proteinase inhibitor (MPI): separate expression of the COOH-terminal domain yields an active inhibitor of three different proteinases.

Authors:  B Meckelein; T Nikiforov; A Clemen; H Appelhans
Journal:  Protein Eng       Date:  1990-01

8.  Proteinase inhibitory activities of antileukoprotease are represented by its second COOH-terminal domain.

Authors:  J A Kramps; C van Twisk; H Appelhans; B Meckelein; T Nikiforov; J H Dijkman
Journal:  Biochim Biophys Acta       Date:  1990-04-19

9.  Neutrophil elastase cleaves C3bi on opsonized pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch.

Authors:  M F Tosi; H Zakem; M Berger
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

10.  Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor.

Authors:  L Björck; P Akesson; M Bohus; J Trojnar; M Abrahamson; I Olafsson; A Grubb
Journal:  Nature       Date:  1989-01-26       Impact factor: 49.962

View more
  96 in total

Review 1.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Urethral cytokine and immune responses in Chlamydia trachomatis-infected males.

Authors:  M S Pate; S R Hedges; D A Sibley; M W Russell; E W Hook; J Mestecky
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

3.  The innate immune system: gatekeeper to the female reproductive tract.

Authors:  Charles R Wira; John V Fahey
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

4.  A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein.

Authors:  Adam Clauss; Hans Lilja; Ake Lundwall
Journal:  Biochem J       Date:  2002-11-15       Impact factor: 3.857

Review 5.  Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor.

Authors:  Stergios Doumas; Alexandros Kolokotronis; Panagiotis Stefanopoulos
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Estradiol selectively regulates innate immune function by polarized human uterine epithelial cells in culture.

Authors:  J V Fahey; J A Wright; L Shen; J M Smith; M Ghosh; R M Rossoll; C R Wira
Journal:  Mucosal Immunol       Date:  2008-05-14       Impact factor: 7.313

7.  The inhibitory effect of secretory leukocyte protease inhibitor (SLPI) on formation of neutrophil extracellular traps.

Authors:  Katarzyna Zabieglo; Pawel Majewski; Monika Majchrzak-Gorecka; Agnieszka Wlodarczyk; Beata Grygier; Aneta Zegar; Monika Kapinska-Mrowiecka; Antonina Naskalska; Krzysztof Pyrc; Adam Dubin; Sharon M Wahl; Joanna Cichy
Journal:  J Leukoc Biol       Date:  2015-04-27       Impact factor: 4.962

8.  Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation.

Authors:  Sinéad Weldon; Paul McNally; Noel G McElvaney; J Stuart Elborn; Danny F McAuley; Julien Wartelle; Abderrazzaq Belaaouaj; Rodney L Levine; Clifford C Taggart
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells.

Authors:  Nick Devoogdt; Gholamreza Hassanzadeh Ghassabeh; Jing Zhang; Lea Brys; Patrick De Baetselier; Hilde Revets
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-05       Impact factor: 11.205

10.  Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Authors:  Esra Fakioglu; Sarah S Wilson; Pedro M M Mesquita; Ehsan Hazrati; Natalia Cheshenko; John A Blaho; Betsy C Herold
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.